Early-stage non-small cell lung cancer, EGFR and ALK-negative

Active Ingredient: Atezolizumab

Indication for Atezolizumab

Population group: only adults (18 years old or older)
Therapeutic intent: Adjuvant - intent

Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥50% of tumour cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC.

For this indication, competent medicine agencies globally authorize below treatments:

840 mg every 2 weeks or 1,200 mg every 3 weeks or 1,680 mg every 4 weeks for 1 year

For:

Dosage regimens

Regimen A: Intravenous, 840 milligrams atezolizumab, once every 2 weeks, over the duration of 1 year.

Regimen B: Intravenous, 1,200 milligrams atezolizumab, once every 3 weeks, over the duration of 1 year.

Regimen C: Intravenous, 1,680 milligrams atezolizumab, once every 4 weeks, over the duration of 1 year.

Detailed description

The recommended dose of atezolizumab is either 840 mg administered intravenously every two weeks, or 1 200 mg administered intravenously every three weeks, or 1 680 mg administered intravenously every four weeks.

Duration of treatment

For 1 year unless disease recurrence or unacceptable toxicity. Treatment duration for more than 1 year was not studied.

Delayed or missed doses

If a planned dose of atezolizumab is missed, it should be administered as soon as possible. The schedule of administration must be adjusted to maintain the appropriate interval between doses.

Dose modifications during treatment

Dose reductions of atezolizumab are not recommended.

Dosage considerations

The infusions must not be administered as an intravenous push or bolus.

The initial dose of atezolizumab must be administered over 60 minutes. If the first infusion is well tolerated, all subsequent infusions may be administered over 30 minutes.

Active ingredient

Atezolizumab

Atezolizumab is an Fc-engineered, humanised immunoglobulin G1 (IgG1) monoclonal antibody that directly binds to PD-L1 and provides a dual blockade of the PD-1 and B7.1 receptors, releasing PD-L1/PD-1 mediated inhibition of the immune response, including reactivating the antitumour immune response without inducing antibody-dependent cellular cytotoxicity.

Read more about Atezolizumab

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.